Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

被引：0
|
作者：
Alessi, Joao Victor Machado
Ricciuti, Biagio
Aguilar, Elizabeth Jimenez
Hong, Fangxin
Wei, Zihan
Nishino, Mizuki
Plodkowski, Andrew J.
Sawan, Peter
Luo, Jia
Rizvi, Hira
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Biostat Core, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9568
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes
    Tibaldi, Carmelo
    Mazzoni, Francesca
    Scotti, Vieri
    Vasile, Enrico
    Pozzessere, Daniele
    Stasi, Irene
    Camerini, Andrea
    Federici, Francesca
    Meoni, Giulia
    Caparello, Chiara
    Turrini, Marianna
    Rossi, Virginia
    Ciccone, Lucia Pia
    Pecora, Irene
    Fantechi, Beatrice
    Antonuzzo, Lorenzo
    Giannarelli, Diana
    Baldini, Editta
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (07) : 1278 - 1285
  • [22] Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.
    Hamai, Kosuke
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Hélène Doubre
    Laurent Greillier
    Grégoire Justeau
    Charles Ricordel
    Aurélie Swalduz
    Hubert Curcio
    Olivier Bylicki
    Jean-Bernard Auliac
    Florian Guisier
    Laurence Bigay-Game
    Marie Bernardi
    Julian Pinsolle
    Karim Amrane
    Chantal Decroisette
    Renaud Descourt
    Christos Chouaid
    Margaux Geier
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15095 - 15102
  • [24] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Doubre, Helene
    Greillier, Laurent
    Justeau, Gregoire
    Ricordel, Charles
    Swalduz, Aurelie
    Curcio, Hubert
    Bylicki, Olivier
    Auliac, Jean-Bernard
    Guisier, Florian
    Bigay-Game, Laurence
    Bernardi, Marie
    Pinsolle, Julian
    Amrane, Karim
    Decroisette, Chantal
    Descourt, Renaud
    Chouaid, Christos
    Geier, Margaux
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15095 - 15102
  • [25] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
    Lee, Young Joo
    Kim, Heung Tae
    Han, Ji-Youn
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Sung, Ji-Hyun
    Lee, Jin Soo
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 361 - 368
  • [26] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
    Reck, Martin
    Remon, Jordi
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
  • [27] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients
    Schulze, Arik Bernard
    Schmidt, Lars Henning
    JOURNAL OF THORACIC DISEASE, 2017, 9 (04) : E384 - E386
  • [29] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [30] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
    Banna, G. L.
    Cortellini, A.
    Cortinovis, D. L.
    Tiseo, M.
    Aerts, J. G. J., V
    Barbieri, F.
    Giusti, R.
    Bria, E.
    Grossi, F.
    Pizzutilo, P.
    Berardi, R.
    Morabito, A.
    Genova, C.
    Mazzoni, F.
    Di Noia, V
    Signorelli, D.
    Gelibter, A.
    Macerelli, M.
    Rastelli, F.
    Chiari, R.
    Rocco, D.
    Gori, S.
    De Tursi, M.
    Di Marino, P.
    Mansueto, G.
    Zoratto, F.
    Filetti, M.
    Montrone, M.
    Citarella, F.
    Marco, R.
    Cantini, L.
    Nigro, O.
    D'Argento, E.
    Buti, S.
    Minuti, G.
    Landi, L.
    Guaitoli, G.
    Lo Russo, G.
    De Toma, A.
    Donisi, C.
    Friedlaender, A.
    De Giglio, A.
    Metro, G.
    Porzio, G.
    Ficorella, C.
    Addeo, A.
    ESMO OPEN, 2021, 6 (02)
12345